WO2024105553 - BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS
National phase entry:
Publication Number
WO/2024/105553
Publication Date
23.05.2024
International Application No.
PCT/IB2023/061469
International Filing Date
14.11.2023
Title **
[English]
BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS
[French]
HÉTÉROCYCLES BICYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE WRN
Applicants **
NOVARTIS AG
Inventors
ZECRI, Frederic
SCHOEPFER, Joseph
MOEBITZ, Henrik
SCHMIEDEBERG, Niko
HAMON, Jacques
HINRICHS, Juergen Hans-Hermann
STRANG, Ross
FUREGATI, Markus
NOCITO, Sandro
GONG, Wanben
YU, Huangchao
Priority Data
PCT/CN2022/132256
16.11.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4632 | |
| EPO | Filing, Examination, Granting | 28325 | |
| Japan | Filing, Examination, Granting | 2958 | |
| South Korea | Filing, Examination, Granting | 3576 | |
| USA | Filing, Examination, Granting | 15940 |
Total:
55,431
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
, R, M, L, W, T, V, Y, K, J, A and y are as described in the Summary of the Invention, therapeutic uses, research uses and a method for manufacturing the compounds of the invention. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.[French]
, R, M, L, W, T, V, Y, K, J, A et Y étant tels que décrits dans le résumé de l'invention, des utilisations thérapeutiques, des utilisations à des fins de recherche et un procédé de fabrication des composés de l'invention. La présente invention concerne en outre une combinaison d'agents pharmacologiquement actifs et une composition pharmaceutique.